5.32
5.32 (-0.20%)
As of Feb 24, 2021
Viracta Therapeutics, Inc. [SNSS]
Source:
Company Overview
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide.
| Country | United States |
| Headquarters | cardiff, california |
| Phone Number | ( 858 ) 400-8470 |
| Industry | manufacturing |
| CEO | Mark Rothera |
| Website | www.viracta.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-10.2 |
| Net Income | $-10.6 |
| Net Cash | $0.8 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -26.8% |
| Profit as % of Stockholder Equity | 159.5% |
Management Effectiveness
| Return on Equity | 159.5% |
| Return on Assets | -48.1% |
| Turnover Ratio | |
| EBITA | $-10.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $22 |
| Total Liabilities | $28.6 |
| Operating Cash Flow | $-24.8 |
| Investing Cash Flow | $34.1 |
| Financing Cash Flow | $-8.5 |
